These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24859049)

  • 21. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.
    Huang W; Eshleman SH; Toma J; Fransen S; Stawiski E; Paxinos EE; Whitcomb JM; Young AM; Donnell D; Mmiro F; Musoke P; Guay LA; Jackson JB; Parkin NT; Petropoulos CJ
    J Virol; 2007 Aug; 81(15):7885-93. PubMed ID: 17507467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site.
    Clevestig P; Pramanik L; Leitner T; Ehrnst A
    J Gen Virol; 2006 Mar; 87(Pt 3):607-612. PubMed ID: 16476981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability].
    Hei FX; Hong KX; Song YH; Tang HL; Peng H; Xu JQ; Xing H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1968-72. PubMed ID: 15730807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in HIV-1 gp120 V3 region are necessary but not sufficient for coreceptor switching in CRF07_BC in China.
    Zhang L; Ma L; Wang Z; Wang Y; Zhang J; Wang H; Shao Y
    PLoS One; 2014; 9(3):e93426. PubMed ID: 24676404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection.
    Li Y; Rey-Cuille MA; Hu SL
    AIDS Res Hum Retroviruses; 2001 Nov; 17(16):1473-9. PubMed ID: 11709091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Position 22 of the V3 loop is associated with HIV infectivity.
    Wei XM; Xu HF; Cheng XD; Bu N; Zhou HZ
    Arch Virol; 2017 Mar; 162(3):637-643. PubMed ID: 27815696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
    Mori T; Boyd MR
    Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry.
    Li Y; Yang D; Wang JY; Yao Y; Zhang WZ; Wang LJ; Cheng DC; Yang FK; Zhang FM; Zhuang M; Ling H
    PLoS One; 2014; 9(1):e86083. PubMed ID: 24465884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.
    Pollakis G; Kang S; Kliphuis A; Chalaby MI; Goudsmit J; Paxton WA
    J Biol Chem; 2001 Apr; 276(16):13433-41. PubMed ID: 11278567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolution of human immunodeficiency virus type-1 (HIV-1) envelope molecular properties and coreceptor use at all stages of infection in an HIV-1 donor-recipient pair.
    Edo-Matas D; Rachinger A; Setiawan LC; Boeser-Nunnink BD; van 't Wout AB; Lemey P; Schuitemaker H
    Virology; 2012 Jan; 422(1):70-80. PubMed ID: 22047989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins.
    Wang J; Babcock GJ; Choe H; Farzan M; Sodroski J; Gabuzda D
    Virology; 2004 Jun; 324(1):140-50. PubMed ID: 15183061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
    Fernàndez G; Llano A; Esgleas M; Clotet B; Esté JA; Martínez MA
    J Gen Virol; 2006 May; 87(Pt 5):1285-1294. PubMed ID: 16603531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of HIV-1 subtype C envelope V3 to V5 regions in viral entry, coreceptor utilization and replication efficiency in primary T-lymphocytes and monocyte-derived macrophages.
    Sundaravaradan V; Das SR; Ramakrishnan R; Sehgal S; Gopalan S; Ahmad N; Jameel S
    Virol J; 2007 Nov; 4():126. PubMed ID: 18036244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
    Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
    Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
    Shi Y; Brandin E; Vincic E; Jansson M; Blaxhult A; Gyllensten K; Moberg L; Broström C; Fenyö EM; Albert J
    J Gen Virol; 2005 Dec; 86(Pt 12):3385-3396. PubMed ID: 16298986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.
    Dervillez X; Klaukien V; Dürr R; Koch J; Kreutz A; Haarmann T; Stoll M; Lee D; Carlomagno T; Schnierle B; Möbius K; Königs C; Griesinger C; Dietrich U
    J Virol; 2010 Oct; 84(19):10131-8. PubMed ID: 20660187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.